BIOMAT Database Logo BIOMAT Database Logo

[Inhalation and peroral mucolytic therapy in mucoviscidosis in children]. 1996

A K Uglitskikh, and M A Khan, and S V Sharapov, and N I Kapranov, and L F Plisko

The paper summarizes the results of clinical studies of 98 children with mucoviscidosis whose age was 7 to 18 years. There is research evidence for possibility and expediency of using new classes of mucolytic agents in the therapy of mucoviscidosis in children. Analysis of the rheological properties of sputum showed the advantage of inhalation route of mucolytics over their oral administration. There is evidence for the advantage of mucosolvan over carbocysteine and unithiol via all routes of administration, the optimal methods of administration and differentiated indications have been developed.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D012119 Respiration The act of breathing with the LUNGS, consisting of INHALATION, or the taking into the lungs of the ambient air, and of EXHALATION, or the expelling of the modified air which contains more CARBON DIOXIDE than the air taken in (Blakiston's Gould Medical Dictionary, 4th ed.). This does not include tissue respiration ( Breathing
D002233 Carbocysteine A compound formed when iodoacetic acid reacts with sulfhydryl groups in proteins. It has been used as an anti-infective nasal spray with mucolytic and expectorant action. 3-(Carboxymethylthio)alanine,Carbocysteine, L-Isomer,Mucodine,Mucodyne,Mukodin,Rhinathiol,S-(Carboxymethyl)-L-cysteine,S-Carboxymethylcysteine,Thiodril,Carbocysteine, L Isomer,L-Isomer Carbocysteine,S Carboxymethylcysteine
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005100 Expectorants Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. Expectorant,Mucolytic,Mucolytic Agent,Mucolytic Agents,Mucolytics,Agent, Mucolytic,Agents, Mucolytic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol

Related Publications

A K Uglitskikh, and M A Khan, and S V Sharapov, and N I Kapranov, and L F Plisko
[Amiloride inhalation therapy in mucoviscidosis].
May 1993, Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde,
A K Uglitskikh, and M A Khan, and S V Sharapov, and N I Kapranov, and L F Plisko
[Aerosol tent and inhalation therapy of mucoviscidosis].
August 1972, Zeitschrift fur Allgemeinmedizin,
A K Uglitskikh, and M A Khan, and S V Sharapov, and N I Kapranov, and L F Plisko
[Inhalation or peroral therapy with bronchospasmolytics].
January 1977, Wiener medizinische Wochenschrift (1946),
A K Uglitskikh, and M A Khan, and S V Sharapov, and N I Kapranov, and L F Plisko
[Mucolytic agents for inhalation].
December 1970, Bollettino chimico farmaceutico,
A K Uglitskikh, and M A Khan, and S V Sharapov, and N I Kapranov, and L F Plisko
[On mucoviscidosis in children. Diagnosis and therapy].
January 1966, Medizinische Monatsschrift,
A K Uglitskikh, and M A Khan, and S V Sharapov, and N I Kapranov, and L F Plisko
[Physical therapy in children with asthma and mucoviscidosis].
February 1992, Kinderkrankenschwester : Organ der Sektion Kinderkrankenpflege,
A K Uglitskikh, and M A Khan, and S V Sharapov, and N I Kapranov, and L F Plisko
Inhalation therapy in children.
January 1982, European journal of respiratory diseases. Supplement,
A K Uglitskikh, and M A Khan, and S V Sharapov, and N I Kapranov, and L F Plisko
Peroral polypeptide delivery. A comparative in vitro study of mucolytic agents.
September 1999, Arzneimittel-Forschung,
A K Uglitskikh, and M A Khan, and S V Sharapov, and N I Kapranov, and L F Plisko
Mucolytic and mucokinetic therapy.
August 1996, Pulmonary pharmacology,
A K Uglitskikh, and M A Khan, and S V Sharapov, and N I Kapranov, and L F Plisko
Mucolytic therapy in asthma.
June 1961, Annals of allergy,
Copied contents to your clipboard!